The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
about
Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorptionAugmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphateFunctional roles of aspartate residues of the proton-coupled folate transporter (PCFT-SLC46A1); a D156Y mutation causing hereditary folate malabsorption.Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorptionHypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line.Identification of Tyr residues that enhance folate substrate binding and constrain oscillation of the proton-coupled folate transporter (PCFT-SLC46A1).Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1)A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding.Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.Functional roles of the A335 and G338 residues of the proton-coupled folate transporter (PCFT-SLC46A1) mutated in hereditary folate malabsorption.Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed.Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitorRole of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1.The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer.The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro
P2860
Q33402047-FAA7E068-79A6-4C2D-AF18-66BFE943DDDFQ33628778-8A4F64A7-E0BF-49B6-A19D-6956486D1C25Q34091240-D68FA211-DF74-44A0-A4A7-D4801B70A2D4Q34129760-946BCC99-5BCC-46E9-875F-984238F30ACCQ34272508-47A01C12-828F-4990-83E9-BEE6E0FAFAF3Q34450436-EE6A49B9-143D-4F83-AB8C-8D72D2823E5BQ34686810-09A0E6B9-3A4A-401F-9014-F7B545382154Q34784792-24AE4950-B844-47CD-A8D2-AE81663BA5A5Q34851106-5716C4B6-E2B4-49C0-A8AC-21D6EFED72BCQ34996747-4AB40387-2303-40F0-B856-D82361D40FBCQ35437120-F228EA1B-DFE6-4A2B-B139-6F55F2A1CF63Q35688514-FA4D7F35-698D-43C5-B635-7B63706CA278Q35993489-CE3C59CC-5D84-49E1-8484-ED91B9506C64Q36294436-8F885657-2A36-4D4E-B41F-7405406729D6Q36312791-2B372DDF-C8FF-4A3C-8B39-0226A10F035CQ36441443-962DDC85-F771-4057-8360-ACC7654C4289Q36779095-86583BE8-5BCF-47A5-85AE-58DF0499F945Q37200566-2B492716-FF9D-443C-ADA9-BAC30EF28815Q37264121-23FB777A-B1C4-43D2-8197-8BFF875066BDQ37645190-34791E88-4C81-4C62-B282-1E46173E117FQ39535518-E4F9E904-A010-42AB-8E17-50A26ABB3316
P2860
The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
The mechanism of transport of ...... red transport of methotrexate.
@en
The mechanism of transport of the multitargeted antifolate
@nl
type
label
The mechanism of transport of ...... red transport of methotrexate.
@en
The mechanism of transport of the multitargeted antifolate
@nl
prefLabel
The mechanism of transport of ...... red transport of methotrexate.
@en
The mechanism of transport of the multitargeted antifolate
@nl
P2093
P1476
The mechanism of transport of ...... ired transport of methotrexate
@en
P2093
P304
P407
P577
2000-09-01T00:00:00Z